
    
      The aim of VACIRiSS trial is to evaluate the immunogenicity and heterologous effects of
      single dose 13-valent conjugate pneumococcal vaccine (PCV-13) in preventing infection related
      rehospitalisation in sepsis survivors and to collect outcome event data with necessary
      precision to inform future definitive trial design.
    
  